What does MILPHARMA do?

MILPHARMA is a pharmacy in Riemst. Private Limited, started on 2 October 2017, 1 establishment.

What is the address of MILPHARMA?

The registered office of MILPHARMA is located at Elderenweg 26, 3770 Riemst.

Is MILPHARMA still active?

Yes. According to the CBE (30 October 2026) MILPHARMA is active, legal situation “Normale toestand”, started on 2 October 2017.

Is MILPHARMA registered on Peppol?

Yes, MILPHARMA is registered on the Peppol network with ID 0208:0681995815.

What is the enterprise number of MILPHARMA?

The enterprise number of MILPHARMA is BE0681995815.

When was MILPHARMA founded?

MILPHARMA was founded on 2 October 2017.

Who are the directors of MILPHARMA?

According to the 2025 annual accounts, the directors of MILPHARMA are: Apotheek Pierlet Helena.

Is MILPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 October 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did MILPHARMA make in 2025?

MILPHARMA posted a profit after taxes of € 93,986 in financial year 2025.

What is the revenue of MILPHARMA?

As a small company, MILPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 133,781.

How many employees does MILPHARMA have?

According to the 2025 annual accounts, MILPHARMA has 0 full-time equivalents (FTE).

MILPHARMA (Private Limited) - Riemst - BE0681995815

Dossier MILPHARMA, printed on 30 October 2026 from databakkes.be/en/0681995815/milpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MILPHARMA from Riemst, company number BE0681995815, closed financial year 2025 with a result of € 93,986 after tax. For that financial year MILPHARMA recorded a gross margin of € 133,781 and equity of € 141,468. Compared with financial year 2024, the result moved from € 90,562 to € 93,986. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 5, 2026.

What it is worth Growing

€ 141,468

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 93,986

▲ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 92,465

▼ 40% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 93,700 paid out

100 % of the profit went to the shareholders, mostly to APOTHEEK PIERLET (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 103

▲ 202% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,324

▼ 40% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 205,156

▼ 9% vs 2024

€ 20,260 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 55,275

▲ 32% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 324

▲ € 311 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 101,867 Gross margin 2022: € 101,867 First fiscal year in the series	€ 116,106 Gross margin 2023: € 116,106 ▲ 14% vs 2022 (€ 101,867) Favourable step	€ 139,642 Gross margin 2024: € 139,642 ▲ 20% vs 2023 (€ 116,106) Favourable step	€ 133,781 Gross margin 2025: € 133,781 ▼ 4% vs 2024 (€ 139,642) Unfavourable step	▼ 4%
Profit after taxes	€ 91,002 Profit after taxes 2022: € 91,002 First fiscal year in the series	€ 77,797 Profit after taxes 2023: € 77,797 ▼ 15% vs 2022 (€ 91,002) Unfavourable step	€ 90,562 Profit after taxes 2024: € 90,562 ▲ 16% vs 2023 (€ 77,797) Favourable step	€ 93,986 Profit after taxes 2025: € 93,986 ▲ 4% vs 2024 (€ 90,562) Favourable step	▲ 4%
Equity	€ 137,524 Equity 2022: € 137,524 First fiscal year in the series	€ 140,820 Equity 2023: € 140,820 ▲ 2% vs 2022 (€ 137,524) Favourable step	€ 141,183 Equity 2024: € 141,183 Unchanged (€ 140,820) Favourable step	€ 141,468 Equity 2025: € 141,468 Unchanged (€ 141,183) Favourable step
Total debts	€ 378,362 Total debts 2022: € 378,362 First fiscal year in the series	€ 415,263 Total debts 2023: € 415,263 ▲ 10% vs 2022 (€ 378,362) Unfavourable step	€ 440,865 Total debts 2024: € 440,865 ▲ 6% vs 2023 (€ 415,263) Unfavourable step	€ 361,487 Total debts 2025: € 361,487 ▼ 18% vs 2024 (€ 440,865) Favourable step	▼ 18%
Cash	€ 104,685 Cash 2022: € 104,685 First fiscal year in the series	€ 119,590 Cash 2023: € 119,590 ▲ 14% vs 2022 (€ 104,685) Favourable step	€ 155,284 Cash 2024: € 155,284 ▲ 30% vs 2023 (€ 119,590) Favourable step	€ 92,465 Cash 2025: € 92,465 ▼ 40% vs 2024 (€ 155,284) Unfavourable step	▼ 40%
Land & buildings	€ 21,840 Land & buildings 2022: € 21,840 First fiscal year in the series	€ 47,018 Land & buildings 2023: € 47,018 ▲ 115% vs 2022 (€ 21,840) Unchanged	€ 43,537 Land & buildings 2024: € 43,537 ▼ 7% vs 2023 (€ 47,018) Unchanged	€ 40,055 Land & buildings 2025: € 40,055 ▼ 8% vs 2024 (€ 43,537) Unchanged	▼ 8%
Retained profit	€ 118,924 Retained profit 2022: € 118,924 First fiscal year in the series	€ 122,220 Retained profit 2023: € 122,220 ▲ 3% vs 2022 (€ 118,924) Favourable step	€ 122,583 Retained profit 2024: € 122,583 Unchanged (€ 122,220) Favourable step	€ 122,868 Retained profit 2025: € 122,868 Unchanged (€ 122,583) Favourable step
Dividend	€ 28,700 Dividend 2022: € 28,700 First fiscal year in the series	€ 74,500 Dividend 2023: € 74,500 ▲ 160% vs 2022 (€ 28,700) Unchanged	€ 90,200 Dividend 2024: € 90,200 ▲ 21% vs 2023 (€ 74,500) Unchanged	€ 93,700 Dividend 2025: € 93,700 ▲ 4% vs 2024 (€ 90,200) Unchanged	▲ 4%
Bank debt	€ 71,497 Bank debt 2022: € 71,497 First fiscal year in the series	€ 244,253 Bank debt 2023: € 244,253 ▲ 242% vs 2022 (€ 71,497) Unfavourable step	€ 224,938 Bank debt 2024: € 224,938 ▼ 8% vs 2023 (€ 244,253) Favourable step	€ 205,156 Bank debt 2025: € 205,156 ▼ 9% vs 2024 (€ 224,938) Favourable step	▼ 9%
Balance sheet total	€ 515,885 Balance sheet total 2022: € 515,885 First fiscal year in the series	€ 556,084 Balance sheet total 2023: € 556,084 ▲ 8% vs 2022 (€ 515,885) Unchanged	€ 582,048 Balance sheet total 2024: € 582,048 ▲ 5% vs 2023 (€ 556,084) Unchanged	€ 502,955 Balance sheet total 2025: € 502,955 ▼ 14% vs 2024 (€ 582,048) Unchanged	▼ 14%

Key figures of MILPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MILPHARMA?

What happened at MILPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 5, 2026 New annual accounts for financial year 2025: profit of € 93,986 (▲ 4% vs 2024). filed late Source: NBB ↗
Oct 2, 2017 New establishment in Riemst. KBO
Oct 2, 2017 Start of the company according to the CBE. KBO

In short

From € 91,002 profit in 2022 to € 93,986 profit in 2025.

Paid € 10,196 in corporate taxes since 2022.

Best year ever: 2025, with € 93,986 profit.

Paid out € 287,100 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

APOTHEEK PIERLET 100%

The stake of APOTHEEK PIERLET comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

MILPHARMA

Behind MILPHARMA is Apotheek Pierlet Helena. The shares are held by APOTHEEK PIERLET (100%).

Directors

According to the 2025 annual accounts

Apotheek Pierlet Helena

Director · represented by Pierlet Helena

Shareholders

APOTHEEK PIERLET

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Elderenweg 26

3770 Riemst

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK PIERLET same network

€ 100,223 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0681.995.815

VAT number

BE 0681.995.815

Registered office

Elderenweg 26, 3770 Riemst

Names & denominations

MILPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 October 2017

Peppol

Active · Active since 4 Jul 2025

Activities · NACE

Detailhandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

MILPHARMA

Financials

What happened to MILPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions